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Abstract
Background: Accuracy of high sensitive troponin (hs-cTn) to detect coronary artery disease (CAD) in 
patients with renal insufficiency is not established. The aim of this study was to evaluate the prognostic 
role of hs-cTn T and I in patients with chronic kidney disease (CKD).
Methods: All consecutive patients with chest pain, renal insufficiency (eGFR < 60 mL/min/1.73 m2) 
and high sensitive troponin level were included. The predictive value of baseline and interval troponin 
(hs-cTnT and hs-cTnI) for the presence of CAD was assessed.
Results: One hundred and thirteen patients with troponin I and 534 with troponin T were included, 
with 95 (84%) and 463 (87%) diagnosis of CAD respectively. There were no differences in clinical, 
procedural and outcomes between the two assays. For both, baseline hs-cTn values did not differ be-
tween patients with/without CAD showing low area under the curve (AUC). For interval levels, hs-cTnI 
was significantly higher for patients with CAD (0.2 ± 0.8 vs. 8.9 ± 4.6 ng/mL; p = 0.04) and AUC 
was more accurate for troponin I than hs-cTnT (AUC 0.85 vs. 0.69). Peak level was greater for hs-cTnI  
in patients with CAD or thrombus (0.4 ± 0.6 vs. 15 ± 20 ng/mL; p = 0.02; AUC 0.87: 0.79–0.93); no 
differences were found for troponin T assays (0.8 ± 1.5 vs. 2.2 ± 3.6 ng/mL; p = 1.7), with lower AUC 
(0.73: 0.69–0.77). Peak troponin levels (both T and I) independently predicted all cause death at 30 days.
Conclusions: Patients with CKD presenting with altered troponin are at high risk of coronary disease. 
Peak level of both troponin assays predicts events at 30 days, with troponin I being more accurate than 
troponin T. (Cardiol J 2017; 24, 2: 139–150)
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Introduction
Accelerated atherosclerosis increases the risk 
of acute myocardial infarction (AMI) in patients 
with chronic kidney disease (CKD) [1–4] compared 
with general population. Moreover, after a coronary 
thrombotic event, mortality rates are extremely 
elevated, due to peri-procedural complications and 
a high risk of recurrent events [5, 6] also due to com-
plicated and technically challenging lesions [7–9].
Cardiac troponins (cTn, either the T or I iso-
form) are the preferred biomarkers measured in 
patients with suspected AMI. Recently accuracy 
of high-sensitivity cTn assays (hs-cTn) have been 
demonstrated to be up to 96% [10]. However this 
study excluded patients with a reduced renal clear-
ance, who have a greater prevalence of persistently 
elevated cTn compared with non-CKD patients. 
Many explanations have been suggested for this. 
While it appears unlikely that this could be related 
only to reduced clearance, subclinical subacute 
cardiac damage or even previous subclinical myo-
cardial necrosis or left ventricular hypertrophy [11] 
may be causative.
In this population the diagnosis of acute coro-
nary syndromes (ACS) can be particularly challeng-
ing. Electrocardiograms are frequently abnormal 
because of a higher prevalence of left ventricular 
hypertrophy and electrolyte imbalances, while 
persistent elevation of cTn represents a frequent 
finding. A high percentage of CKD patients have 
increased levels of troponin T and troponin I, which 
decreases the accuracy in predicting cardiac isch-
emia and diagnosing AMI [12–14]. 
Moreover, coronary computed tomography 
seems unlikely to be useful, because of high rates 
of coronary calcification [15].
Only a few studies [16] have tested the ac-
curacy of hs-cTn in ACS settings, but patients 
included had a median clearance higher than 
60 mL/min/m2, consequently limiting their applica-
bility into everyday practice.
Methods
This study conforms to the STROBE guide-
lines [17].
The study was approved by the local bioethical 
committee; the retrospective nature of the study 
did not required anticipated patient consent.
Study design, setting and participants
Retrospectively all patients presented to the 
Emergency Department (ED) with chest pain of 
recent onset (less than 6 hours) in 7 centres (Turin, 
Thoraxcenter, Edinburgh, Bologna, Siena, Catania, 
Krakow) between 2009 and 2011.
Inclusion criteria were: 1) elevation of hs-cTn 
levels above the upper limit of reference at base-
line and 2) renal clearance below 60 mL/min/m2, 
elaborated according to Modification of Diet in 
Renal Disease (MDRD) formula [15].
Clinical variables and end points
Troponin levels assessed 3 and 6 h after ED 
presentation were recorded along with peak level 
before coronary angiography, relative increase of 
the second level compared to baseline and relative 
increase of the peak level compared to baseline. 
Age, gender, cardiovascular risk factors and renal 
clearance on admission (elaborated through MDRD 
formula [15]) were also collected. Cardiovascular 
risk factors were appraised during ED or cardiology 
ward stay as part of usual care, according to current 
guidelines for hypertension, hyperlipidemia and 
diabetes mellitus (both already known and new 
diagnosis) [18–20]. Ejection fraction on admission 
was also assessed.
All these variables were collected separately 
for patients with high sensitive troponin T and I. 
All clinical, procedural and outcomes were analyzed 
according to tertiles of troponin. 
Venous blood sampling was performed at 3 and 
6 h after ED presentation, before coronary angi-
ography and every 24 h thereafter. All samples 
were immediately transported to the laboratory, 
where plasma was separated with standard cen-
trifugation. Every center used its own laboratory, 
but assays were standardized: exploited assays 
for troponin T were ECLIA Roche Diagnostics 
(with an upper reference limit [99th percentile] of 
0.14 ng/L) and for troponin I high sensitive Abbott-
Architect troponin (with an upper reference limit 
[99th percentile] of 0.26 ng/L).
Accuracy (defined as area under the curve 
[AUC] of the two different assays at 3 and 6 h, at the 
peak and their relative increase to detect coronary 
artery disease (CAD). Significant coronary stenosis 
defined as (more than 50% for left main and 70% 
for other epicardial coronary vessels) or thrombus, 
was the primary end point. Secondary end points 
were incidence of major adverse cardiac events at 
30 days and at follow up defined as a composite 
end point of all cause death, cardiovascular death, 
myocardial infarction, revascularization, target ves-
sel revascularization and stent thrombosis defined 
according to ARC definitions [21, 22] and its single 
components. 
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Statistical analysis
Continuous variables are expressed as mean ± 
± standard deviation and categorical variables are 
presented as counts and percentage were compared 
with c2 test. Normality of troponin values was 
assessed through the Kolmogorov-Smirnov test. 
Continuous variables were compared either with 
ANOVA (if normal distribution) or with Kruskal-
-Wallis (if not normal distribution). A logistic regres- 
sion was performed to evaluate the independent 
predictive power for all cause death at 30 days 
exploiting all features with a significant difference 
(p < 0.10) at univariate analysis. To account for 
different length of follow up, a Cox multivariate 
adjustment with no parsimonious model was ex-
ploited to assess the independent predictive power 
of peak troponin for all cause death [23].
Area under the curve was calculated with 95% 
confidence interval for diagnosis of thrombus or 
significant coronary stenosis for first, second and 
peak of troponin before percutaneous coronary 
intervention, and for relative increase of second on 
first and of peak on second. Sensitivity analysis for 
AUC was also performed according to renal clear-
ance, for those above and below 30 mL/min/m2. 
Correlation between renal function (creatinine and 
clearance) and troponin levels were evaluated with 
Pearson or Rho Sperman, according to parametric 
distribution.
Results
One hundred and thirteen patients with tro-
ponin I assays and 534 with troponin T were includ-
ed. At angiography, a significant coronary stenosis 
or a thrombus was found in 95 (84%) patients with 
hs-cTnI measurements and in 463 (87%) patients 
with hs-cTnT measurements. 
For troponin T patients, 120 (23%) were in 
the lowest tertile of troponin (less than 0.19 ng/ 
/mL), 246 (46%) in the medium (between 0.19 and 
2.4 ng/mL) and 147 (28%) in the highest. For tro-
ponin I, 29 (25%) patients were in the lowest levels 
(less than 0.43 ng/mL), 57 (50%) between 0.43 and 
21 ng/mL, and 27 (25%) in the upper.
Baseline features were similar (Table 1); in 
both groups the GRACE score was significantly 
higher in patients in the upper tertile. Ejection 
fraction evaluated on admission in 83% of patients 
showed a trend towards lower values in both 
groups.
Overall, left main disease was diagnosed in 
67 (13%) and two and three vessel coronary stenosis 
in 191 (41%) and 138 (25%) patients, respectively 
(Table 2). Most patients (403; 78%) were treated 
with percutaneous transluminal angioplasty, while 
only 28 (7%) were managed conservatively.
At 30 days and during the follow-up (Tables 3, 4), 
rates of adverse events were higher in patients in 
the highest tertile, mainly driven by re-infarctions, 
as they were after a follow up of 52 (13–70) months.
For both assays, baseline hs-cTn values were 
recorded after a median of 3.5 (3–6) h and did not 
differ between patients with or without CAD, 
also showed low AUCs (troponin T: AUC 0.61; 
0.56–0.64; sensitivity 73; specificity 49, for patients 
with renal clearance between 30 and 60 mL/min/m2, 
AUC 0.57; 0.51–0.61; sensitivity 65; specificity 
45; for patients with renal clearance less than 
30 mL/min/m2, AUC 0.52; 0.45–0.64; sensitivity 
59; specificity 43; troponin I: AUC 0.61; 0.52–0.71; 
sensitivity 69; specificity 45, for patients with renal 
clearance between 30 and 60 mL/min/m2, AUC 0.57; 
0.51–0.61; sensitivity 65; specificity 45, for patients 
with renal clearance less than 30 mL/min/m2, 
AUC 0.60; 0.57–0.69; sensitivity 64; specificity 49) 
(Fig. 1A, B).
For interval levels (evaluated after 7; 5–13 h), 
hs-cTn I was significantly higher for patients 
with CAD (0.2 ± 0.8 vs. 8.9 ± 4.6 ng/mL; 
p = 0.04; Fig. 2A) but not troponin T (Fig. 2A): 
similarly AUC was more predictive for troponin I 
than hs-cTnT (troponin T: AUC 0.69; 0.64–0.74; 
sensitivity 70; specificity 56, for patients with 
renal clearance between 30 and 60 mL/min/m2, 
AUC 0.65; 0.63–0.68; sensitivity 63; specificity 
49, for patients with renal clearance less than 
30 mL/min/m2, AUC 0.62; 0.58–0.71; sensitivity 58; 
specificity 54; troponin I: AUC 0.85; 0.65–0.92; sen-
sitivity 65; specificity 100, for patients with renal 
clearance between 30 and 60 mL/min/m2, AUC 0.86; 
0.81–0.94; sensitivity 78; specificity 95, for patients 
with renal clearance less than 30 mL/min/m2, 
AUC 0.81; 0.59–0.85; sensitivity 64; specificity 81) 
(Fig. 2B). Also increase of interval on baseline 
level showed the same trend (AUC 0.8; 0.71–0.96 
vs. AUC 0.64; 0.60–0.70; Fig. 3A). 
All these results were consistent after sensi-
tivity analysis was performed according to level of 
renal clearance (Figs. 1–4).
Peak level (recorded after 9.5; 6.5–14 h from 
clinical presentation, Fig. 4A) was greater for hs-
cTnI in patients with CAD or thrombus (0.4 ± 
± 0.6 vs. 15 ± 20 ng/mL; p = 0.02), with an AUC of 
0.87; on the contrary no differences were found for 
troponin T assays (0.8 ± 1.5 vs. 2.2 ± 3.6 ng/mL; 
p = 1.7), with lower AUC (troponin T: AUC 
0.73; 0.69–0.77; sensitivity 83; specificity 51, for 
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patients with renal clearance between 30 and 
60 mL/min/m2, AUC 0.74; 0.65–0.81; sensitivity 84; 
specificity 54, for patients with renal clearance 
less than 30 mL/min/m2, AUC 0.74; 0.63–0.79; 
sensitivity 83; specificity 52; troponin I: AUC 0.87; 
0.79–0.93; sensitivity 73; specificity 91, for patients 
Figure 1. A. First troponin level for patients without 
(on the right) and with (on the left) coronary disease. 
On the left troponin T; on the right troponin I [ng/mL]. 
Hours from presentation: 3.5 (3–6); B. Area under the 
curve (AUC) of first troponin level to detect thrombus 
or significant stenosis for troponin T on the left (AUC 
0.61; 0.56–0.64; sensitivity 73; specificity 49) and for 
troponin I on the right (AUC 0.61; 0.52–0.71; sensitivity 
69; specificity 45).
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with renal clearance between 30 and 60 mL/min/m2, 
AUC 0.88; 0.79–0.95; sensitivity 79; specificity 
90, for patients with renal clearance less than 
30 mL/min/m2, AUC 0.80; 0.76–0.84; sensitivity 65; 
specificity 88) (Fig. 4B).
At logistic regression, two models were per-
formed for each population; in both of them GRACE 
score (OR 2.5; 1.5–5) and peak troponin level (T as 
log of values OR 1.4; 1.1–4.4 and I OR 1.3; 1.1–2.5) 
were independently related to all cause death, 
while only ejection fraction was a predictor of long 
term death (OR 3; 2–4; Fig. 5).
Both for troponin I and T, no significant cor-
relation was found with renal function, evaluated 
with creatinine and renal clearance (Table 5).
Discussion
The main results of this multicenter registry 
are: (a) patients with CKD presenting to the ED 
with alterations of troponin are at high risk of coro-
nary disease; (b) peak level of both troponin assays 
predicts events at 30 days; (c) troponin I may be 
more accurate than troponin T in this population.
High risk of coronary disease in patients with 
even a small reduction of renal function is well 
documented. In primary prevention, a recent study 
involving more than one million patients demon-
strated an incidence of myocardial infarction similar 
in CKD patients compared to diabetic patients [24], 
introducing the concept of renal disease as another 
coronary heart disease equivalent. Actually CKD 
at its different stages is characterized by oxidative 
stress, inflammation, and dyslipidemia, a combina-
tion which promotes accelerated atherosclerosis 
[25, 26]. Oxidation of low-density lipoprotein 
(LDL), endothelial injury and dysfunction, and si-
multaneously compromise high density lipoprotein 
(HDL) represents the primary etiology: moreover 
oxidized lipids promote inflammation, thus reduc-
ing the protective function of HDL [27, 28]. These 
biochemical findings clinically translate into a high 
risk of coronary disease for these patients, which 
currently constitutes up to 80% in our population. 
It should be remembered, however, that the pre-
sent paper is based on a retrospective registry: 
consequently a non indifferent risk of selection 
towards a high risk population may be possible. It 
could have occured at several points of the clinical 
decision making process, from the choice of hospi-
talization for the patient at ED evaluation, to that 
of performing coronary angiography. On the other 
hand, this registry represents a real life pragmatic 
approach, aiming to describe the risk of patients 
clinically depicted as “high risk”.
In an examination of the research, this is the 
first study to demonstrate the prognostic role 
of high sensitivity peak level of troponin (both 
Figure 2. A. Second troponin level for patients without (on the right) and with (on the left) coronary disease. On the 
left troponin T; on the right troponin I [ng/mL]. Hours from presentation: 7 (5–13); B. Area under the curve (AUC) 
of second troponin level to detect thrombus or significant stenosis for troponin T on the left (AUC 0.69;  0.64–0.74; 
sensitivity 70; specificity 56) and for troponin I on the right (AUC 0.85; 0.65–0.92; sensitivity 65; specificity 100).
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Figure 3. A. Area under the curve (AUC) of increment of second on first troponin level to detect thrombus or signifi-
cant stenosis for troponin T on the left (AUC 0.64; 0.60–0.70; sensitivity 58; specificity 69) and for troponin I on the 
right (AUC 0.8; 0.71–0.96; sensitivity 72; specificity 100); B. AUC of increment of peak on first troponin level to detect 
thrombus or significant stenosis for troponin T on the left (AUC 0.69; 0.65–0.74; sensitivity 61; specificity 72) and for 
troponin I on the right (AUC 0.79; 0.69–0.84; sensitivity78; specificity 75).
T and I) in patients with CKD. The role of this 
elevation is well documented for non high sensi-
tive troponin, which was predictive for short and 
long-term risk of death or myocardial infarction in 
ACS patients across all degrees of kidney disease 
[29–31]. Moreover no differences among various 
assays were recently demonstrated in subgroup 
analysis of CRUSADE [32], especially for patients 
reporting higher levels of troponin (for TnT 9% 
vs. 14%; for TnI 6% vs. 14%). Similarly, in pa-
tients with preserved kidney function, hs-cTn 
levels correlated to mid and long term mortality 
[33, 34]. In the present study, prognostic value of 
hsTn (both T and I) was demonstrated for short 
term all cause death, but not all long term. Several 
explanations may be deduced; for these patients 
a slight basal elevation of troponin is very frequent, 
consequently limiting clinical validity of peak level 
[9] and moreover at follow up depressed ejection 
fraction, which is strictly connected to cardiac 
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damage (that is troponin release) may confine 
prognostic role of hs-cTn.
High sensitive TnI was more accurate than 
hsTnT in detecting coronary disease. Both of them 
are derived from genes that are specific to the heart, 
and show the same accuracy and prognostic value 
in patients without renal disease [35, 36]. Patients 
tested with troponin I and T were similar both for 
baseline and procedural features, both for 30 days 
and long term outcomes (see Tables 3 and 4). 
Figure 5. Independent predictors values for 30 days all cause death. Peak troponin level (log) T:I 1.3: (1.1.2.5).
Figure 4. A. Peak troponin level for patients without (on the right) and with (on the left) coronary disease. On the left 
troponin T; on the right troponin I [ng/mL]. Hours from presentation: 9.5 (6.5–14); B. AUC of peak troponin level before 
percutaneous coronary intervention to detect thrombus or significant stenosis for troponin T on the left (AUC 0.73; 
0.69–0.77; sensitivity 83; specificity 51) and for troponin I on the right (AUC 0.87; 0.79–0.93; sensitivity 73; specificity 
91); AUC — area under the curve.
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On the contrary, in the era of non high sensitivity 
troponin, non specific TnT elevations were dem-
onstrated in patients with renal failure [37–39]. 
Many explanations have been provided, from total 
lack of expression of cardiac TnI in non-cardiac 
tissue to less susceptibility of troponin I compared 
to T to proteolysis which is enhanced by uremia. 
In the present population, accuracy of troponin I 
was higher than that of T, stressing the need for 
an accurate choice of assays according to a specific 
population of interest. Performance of hs-cTnT 
was lower than in the recent study of Chenevier-
Gobeaux [16], but median values of clearance 
in that study (75.3; 62.7–91.7 mL/min/1.73 m2) 
were significantly higher than in this study (49: 
35–53), thus explaining limited performance. 
Moreover both for troponin T and I, accuracy was 
higher in patients with less severely reduced renal 
clearance, stressing the need to test these results 
in a prospective way, to increase evidence about 
troponin assays in patients with CKD.
Limitations of the study
This study has some limitations. Firstly, it is 
a retrospective study, with all the inherent risks of bias. 
Moreover hs-cTnT and hs-cTnI were not directly 
compared, but were tested with different popula-
tions. These were however, very similar in baseline 
characteristics, procedural features and outcomes, 
thus allowing indirect comparisons. These findings 
are supported by previous evidence on non high sen-
sitivity troponin. Data about completeness of revas-
cularization were not collected, although we reported 
about revascularization on proximal and consequently 
prognostic vessels. Finally we did not collect data 
about patients without elevated troponin levels, in 
order to focus on a homogeneous population.
Conclusions
Patients with CKD presenting to the ED with 
alterations of troponin are at high risk of coronary 
disease. Peak levels of both troponin assays pre-
dicts events at 30 days, but troponin I may be more 
accurate than troponin T in this population.
Contributions: The Food and Drug Administration 
conceived the paper and took whole responsibility 
of the paper. All the other authors were involved 
for the data collection, analysis and drafting of the 
manuscript.
Conflict of interest: None declared
References
1. Gupta S, de Lemos JA. Use and misuse of cardiac troponins in 
clinical practice. Prog Cardiovasc Dis. 2007; 50(2): 151–165, 
doi: 10.1016/j.pcad.2007.01.002, indexed in Pubmed: 17765476.
2. Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/ 
/WHF Task Force for Universal Definition of Myocardial Infarc-
tion, Authors/Task Force Members Chairpersons, Biomarker 
Subcommittee, ECG Subcommittee, Imaging Subcommittee, 
Classification Subcommittee, Intervention Subcommittee, Trials 
& Registries Subcommittee, Trials & Registries Subcommittee, 
Trials & Registries Subcommittee, Trials & Registries Subcom-
mittee, ESC Committee for Practice Guidelines (CPG), Docu-
ment Reviewers. Third universal definition of myocardial infarc-
tion. J Am Coll Cardiol. 2012; 60(16): 1581–1598, doi: 10.1016/j.
jacc.2012.08.001, indexed in Pubmed: 22958960.
3. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in 
early diagnosis of acute myocardial infarction. N Engl J Med. 
2009; 361(9): 868–877, doi:  10.1056/NEJMoa0903515, indexed 
in Pubmed: 19710485.
4. D’Ascenzo F, Presutti DG, Picardi E, et al. Prevalence and non-
invasive predictors of left main or three-vessel coronary disease: 
evidence from a collaborative international meta-analysis includ-
ing 22 740 patients. Heart. 2012; 98(12): 914–919, doi: 10.1136/ 
/heartjnl-2011-301596, indexed in Pubmed: 22626899.
5. Budano C, Levis M, D’Amico M, et al. Impact of contrast-induced 
acute kidney injury definition on clinical outcomes. Am Heart J. 
2011; 161(5): 963–971, doi:  10.1016/j.ahj.2011.02.004, indexed 
in Pubmed: 21570530.
Table 5. Correlation between troponin T and I and creatinine and renal clearance.
Creatinine  
[mg/dL]
Renal clearance (MDRD)  
[mL/min/1.73 m2]
Troponin I [ng/mL]
First level r = 0.15; p = 0.11 r = –0.07; p = 0.45
Second level r = –0.13; p = 0.45 r = 0.175; p = 0.19
Peak level r = –0.16; p = 0.88 r = 0.17; p = 0.06
Troponin T [ng/mL]
First level r = 0.07; p = 0.15 r = –0.06; p = 0.34
Second level r = –0.13; p = 0.45 r = –0.03; p = 0.61
Peak level r = –0.05; p = 0.56 r = 0.32; p = 0.04
Pearson or Spearman Correlation (r)
www.cardiologyjournal.org 149
Flavia Ballocca et al., High sensitive troponin and renal disease for myocardial infarction
6. D’Ascenzo F, Gonella A, Quadri G, et al. Comparison of morta -
lity rates in women versus men presenting with ST-segment 
elevation myocardial infarction. Am J Cardiol. 2011; 107(5): 
651–654, doi:  10.1016/j.amjcard.2010.10.038, indexed in Pub-
med: 21195375.
7. Huang HD, Alam M, Hamzeh I, et al. Patients with severe 
chronic kidney disease benefit from early revascularization after 
acute coronary syndrome. Int J Cardiol. 2013; 168(4): 3741–3746, 
doi: 10.1016/j.ijcard.2013.06.013, indexed in Pubmed: 23845772.
8. Bataille Y, Plourde G, Machaalany J, et al. Interaction of chronic 
total occlusion and chronic kidney disease in patients under-
going primary percutaneous coronary intervention for acute 
ST-elevation myocardial infarction. Am J Cardiol. 2013; 112(2): 
194–199, doi:  10.1016/j.amjcard.2013.03.010, indexed in Pub-
med: 23601580.
9. Quadri G, D’Ascenzo F, Moretti C, et al. Diffuse coronary dis-
ease: short- and long-term outcome after percutaneous coronary 
intervention. Acta Cardiol. . 2013; 68(2): 151–160, doi: 10.2143/ 
/AC.68.2.2967272, indexed in Pubmed: 23705557.
10. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myo - 
cardial infarction with sensitive cardiac troponin assays. N Engl 
J Med. 2009; 361(9): 858–867, doi:  10.1056/NEJMoa0900428, 
indexed in Pubmed: 19710484.
11. Wang AYM, Lai KN. Use of cardiac biomarkers in end-stage renal 
disease. J Am Soc Nephrol. 2008; 19(9): 1643–1652, doi: 10.1681/ 
/ASN.2008010012, indexed in Pubmed: 18322158.
12. Ellis K, Dreisbach AW, Lertora JL. Plasma elimination of cardiac 
troponin I in end-stage renal disease. South Med J. 2001; 94(10): 
993–996, indexed in Pubmed: 11702827.
13. Wu AHB, Jaffe AS, Apple FS, et al. NACB Writing Group, NACB 
Committee. National Academy of Clinical Biochemistry labora-
tory medicine practice guidelines: use of cardiac troponin and 
B-type natriuretic peptide or N-terminal proB-type natriuretic 
peptide for etiologies other than acute coronary syndromes and 
heart failure. Clin Chem. 2007; 53(12): 2086–2096, doi: 10.1373/ 
/clinchem.2007.095679, indexed in Pubmed: 17954494.
14. Jafari Fesharaki M, Alipour Parsa S, Nafar M, et al. Serum tro-
ponin I level for diagnosis of acute coronary syndrome in patients 
with chronic kidney disease. Iran J Kidney Dis. 2016; 10(1): 
11–16, indexed in Pubmed: 26837675.
15. D’Ascenzo F, Cerrato E, Biondi-Zoccai G, et al. Coronary com-
puted tomographic angiography for detection of coronary artery 
disease in patients presenting to the emergency department 
with chest pain: a meta-analysis of randomized clinical trials. Eur 
Heart J Cardiovasc Imaging. 2013; 14(8): 782–789, doi: 10.1093/
ehjci/jes287, indexed in Pubmed: 23221314.
16. Chenevier-Gobeaux C, Meune C, Freund Y, et al. Influence of 
age and renal function on high-sensitivity cardiac troponin T 
diagnostic accuracy for the diagnosis of acute myocardial infarc-
tion. Am J Cardiol. 2013; 111(12): 1701–1707, doi:  10.1016/j.
amjcard.2013.02.024, indexed in Pubmed: 23540652.
17. http://www.strobe-statement.org/index.php?id = available-checklists.
18. http://mdrd.com/.
19. Mancia G, Fagard R, Narkiewicz K, et al. Task Force for the 
Management of Arterial Hypertension of the European Society 
of Hypertension and the European Society of Cardiology, Task 
Force Members. 2013 ESH/ESC guidelines for the management 
of arterial hypertension: the Task Force for the Management of 
Arterial Hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). Eur 
Heart J. 2013; 34(28): 2159–2219, doi: 10.1093/eurheartj/eht151, 
indexed in Pubmed: 23771844.
20. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College 
of Cardiology/American Heart Association Task Force on Prac-
tice Guidelines. 2013 ACC/AHA guideline on the treatment of 
blood cholesterol to reduce atherosclerotic cardiovascular risk in 
adults: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines. J Am Coll 
Cardiol. 2014; 63: 2889–2934, doi:  10.1016/j.jacc.2013.11.002, 
indexed in Pubmed: 24239923.
21. Jones AG, Knight BA, Baker GC, et al. Practical implications of 
choice of test in National Institute for Health and Clinical Excel-
lence (NICE) guidance for the prevention of type 2 diabetes. Dia-
bet Med. 2013; 30(1): 126–127, doi: 10.1111/dme.12025, indexed 
in Pubmed: 23002907.
22. Thygesen K, Mair J, Giannitsis E, et al. Study Group on Biomark-
ers in Cardiology of ESC Working Group on Acute Cardiac Care. 
How to use high-sensitivity cardiac troponins in acute cardiac 
care. Eur Heart J. 2012; 33(18): 2252–2257, doi:  10.1093/eur-
heartj/ehs154, indexed in Pubmed: 22723599.
23. Cutlip DE, Windecker S, Mehran R, et al. Academic Research 
Consortium. Clinical end points in coronary stent trials: a case 
for standardized definitions. Circulation. 2007; 115(17): 2344– 
–2351, doi:  10.1161/CIRCULATIONAHA.106.685313, indexed 
in Pubmed: 17470709.
24. D’Ascenzo F, Cavallero E, Biondi-Zoccai G, et al. Use and misuse 
of multivariable approaches in interventional cardiology studies 
on drug-eluting stents: a systematic review. J Interv Cardiol. 
2012; 25(6): 611–621, doi:  10.1111/j.1540-8183.2012.00753.x, 
indexed in Pubmed: 22882654.
25. Tonelli M, Muntner P, Lloyd A, et al. Alberta Kidney Disease 
Network. Risk of coronary events in people with chronic kidney 
disease compared with those with diabetes: a population-level 
cohort study. Lancet. 2012; 380(9844): 807–814, doi:  10.1016/
S0140-6736(12)60572-8, indexed in Pubmed: 22717317.
26. Navab KD, Elboudwarej O, Gharif M, et al. Chronic inflamma-
tory disorders and accelerated atherosclerosis: chronic kidney 
disease. Curr Pharm Des. 2011; 17(1): 17–20, indexed in Pub-
med: 21222643.
27. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activ-
ity in chronic kidney disease. Nat Rev Nephrol. 2010; 6: 287–296.
28. D’Ascenzo F, Agostoni P, Abbate A, et al. Atherosclerotic coro-
nary plaque regression and the risk of adverse cardiovascular 
events: a meta-regression of randomized clinical trials. Ath-
erosclerosis. 2013; 226(1): 178–185, doi: 10.1016/j.atherosclero-
sis.2012.10.065, indexed in Pubmed: 23206978.
29. Navab M, Anantharamaiah GM, Reddy ST, et al. Mechanisms of 
disease: proatherogenic HDL--an evolving field. Nat Clin Pract 
Endocrinol Metab. 2006; 2(9): 504–511, doi:  10.1038/ncpend-
met0245, indexed in Pubmed: 16957764.
30. Ryu DR, Park JT, Chung JH, et al. A more appropriate cardiac 
troponin T level that can predict outcomes in end-stage renal 
disease patients with acute coronary syndrome. Yonsei Med J. 
2011; 52(4): 595–602, doi: 10.3349/ymj.2011.52.4.595, indexed 
in Pubmed: 21623601.
31. Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms 
expressed in renal diseased skeletal muscle will not cause false-
positive results by the second generation cardiac troponin T 
assay by Boehringer Mannheim. Clin Chem. 1998; 44(9): 1919–
–1924, indexed in Pubmed: 9732977.
32. Apple FS, Murakami MM, Pearce LA, et al. Predictive value 
of cardiac troponin I and T for subsequent death in end-stage 
renal disease. Circulation. 2002; 106(23): 2941–2945, indexed in 
Pubmed: 12460876.
33. Melloni C, Alexander KP, Milford-Beland S, et al. Crusade In-
vestigators. Prognostic value of troponins in patients with non-
ST-segment elevation acute coronary syndromes and chronic 
kidney disease. Clin Cardiol. 2008; 31(3): 125–129, doi: 10.1002/
clc.20210, indexed in Pubmed: 18383049.
34. Reichlin T, Twerenbold R, Reiter M, et al. Introduction of 
high-sensitivity troponin assays: impact on myocardial infarc-
tion incidence and prognosis. Am J Med. 2012; 125(12): 1205–
1213.e1, doi:  10.1016/j.amjmed.2012.07.015, indexed in Pub-
med: 23164485.
35. Balmelli C, Meune C, Twerenbold R, et al. Comparison of the 
performances of cardiac troponins, including sensitive assays, 
and copeptin in the diagnostic of acute myocardial infarction 
and long-term prognosis between women and men. Am Heart J. 
2013; 166(1): 30–37, doi: 10.1016/j.ahj.2013.03.014, indexed in 
Pubmed: 23816018.
36. Coudrey L. The troponins. Arch Intern Med. 1998; 158(11): 
1173–1180, indexed in Pubmed: 9625396.
37. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prog-
nostic value of troponin in patients with non-ST elevation acute 
coronary syndromes: a meta-analysis. J Am Coll Cardiol. 2001; 
38(2): 478–485, indexed in Pubmed: 11499741.
38. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurate-
ly predicts myocardial injury in renal failure. Nephrol Dial Trans-
plant. 1998; 13(7): 1709–1712, indexed in Pubmed: 9681716.
39. Li D, Keffer J, Corry K, et al. Nonspecific elevation of troponin T 
levels in patients with chronic renal failure. Clin Biochem. 1995; 
28(4): 474–477, indexed in Pubmed: 8521605.
150 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 2
